BELGRADE, Mont., Nov. 17, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development, manufacturing and marketing of orthopedic products for domestic and international markets, announced today the closing of its rights offering (the "Offering") of units at a subscription price of $0.75 per unit, for aggregate gross proceeds to the Company of approximately $3.8 million. Pursuant to the Rights Offering, Xtant sold an aggregate of 5,055,345 units consisting of a total of 5,055,345 shares of common stock and 5,055,345 warrants, with each warrant exercisable to purchase one share of common stock an exercise price of $0.90 for five years from the date of issuance. The warrants are anticipated to commence trading on the OTCBB under the symbol "XTNTW" as early as Wednesday, November 23, 2016. Maxim Group LLC acted as sole dealer manager for the Offering. If you have questions about the offering, please contact Maxim Group LLC, 405 Lexington Avenue, New York, NY 10174, Attention: Syndicate Department, email: firstname.lastname@example.org or telephone 212-895-3745. This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Xtant Medical's registration statement on Form S-1 was declared effective by the U.S. Securities and Exchange Commission (SEC) on October 31, 2016. The final prospectus, prospectus supplement no. 1 thereto dated November 9, 2016, and all of Xtant Medical's SEC filings may be found on the SEC's website at http://www.sec.gov. About Xtant Medical Holdings Xtant Medical Holdings, Inc. (NYSE MKT:XTNT) develops, manufactures and markets class-leading regenerative medicine products and medical devices for domestic and international markets. Xtant products serve the specialized needs of orthopedic and neurological surgeons, including orthobiologics for the promotion of bone healing, implants and instrumentation for the treatment of spinal disease, tissue grafts for the treatment of orthopedic disorders, and biologics to promote healing following cranial, and foot and ankle surgeries. With core competencies in both biologic and non-biologic surgical technologies, Xtant can leverage its resources to successfully compete in global neurological and orthopedic surgery markets. For further information, please visit www.xtantmedical.com. Important Cautions Regarding Forward-looking Statements This press release contains certain disclosures that may be deemed forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to significant risks and uncertainties. Forward-looking statements include statements that are predictive in nature, that depend upon or refer to future events or conditions, or that include words such as "continue," "efforts," "expects," "anticipates," "intends," "plans," "believes," "estimates," "projects," "forecasts," "strategy," "will," "goal," "target," "prospects," "potential," "optimistic," "confident," "likely," "probable" or similar expressions or the negative thereof.